Hyundai Pharmaceutical Co., Ltd.
KRX:004310.KS
4330 (KRW) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 180,762.659 | 162,690.046 | 139,802.753 | 132,965.512 | 134,649.736 | 130,790.769 | 130,480.291 | 120,021.835 | 109,829.32 | 107,836.679 | 108,135.474 | 102,253.367 | 113,046.193 | 111,860.453 | 122,879.077 | 120,520.284 | 111,663.468 |
| Cost of Revenue
| 104,169.922 | 93,852.68 | 83,489.655 | 74,643.953 | 70,965.686 | 70,322.488 | 68,497.094 | 72,883.845 | 67,551.047 | 66,308.308 | 67,424.407 | 62,983.988 | 66,264.057 | 64,016.327 | 71,601.355 | 67,121.503 | 56,331.217 |
| Gross Profit
| 76,592.737 | 68,837.366 | 56,313.098 | 58,321.559 | 63,684.05 | 60,468.282 | 61,983.197 | 47,137.99 | 42,278.273 | 41,528.371 | 40,711.067 | 39,269.379 | 46,782.136 | 47,844.126 | 51,277.722 | 53,398.781 | 55,332.251 |
| Gross Profit Ratio
| 0.424 | 0.423 | 0.403 | 0.439 | 0.473 | 0.462 | 0.475 | 0.393 | 0.385 | 0.385 | 0.376 | 0.384 | 0.414 | 0.428 | 0.417 | 0.443 | 0.496 |
| Reseach & Development Expenses
| 12,230.554 | 8,375.643 | 8,088.955 | 9,620.787 | 11,808.057 | 13,585.756 | 13,128.538 | 6 | 66.806 | 39.67 | 67.691 | 391.589 | 158.886 | 659.634 | 1,813.193 | 3,726.095 | 4,176.815 |
| General & Administrative Expenses
| 10,394.847 | 10,108.298 | 10,974.303 | 9,677.063 | 10,924.8 | 10,902.643 | 10,943.3 | 10,449.356 | 10,012.394 | 10,087.063 | 9,668.098 | 11,690.03 | 10,393.604 | 11,596.687 | 11,174.181 | 9,869.492 | 8,892.636 |
| Selling & Marketing Expenses
| 20,671.139 | 18,068.088 | 11,963.246 | 10,581.407 | 12,813.92 | 12,966.035 | 12,679.838 | 13,404.145 | 10,990.107 | 10,239.958 | 9,253.128 | 9,765.123 | 9,416.259 | 14,044.493 | 14,993.903 | 13,242.316 | 15,482.014 |
| SG&A
| 31,065.986 | 28,176.386 | 22,937.549 | 20,258.47 | 23,738.72 | 23,868.678 | 23,623.138 | 23,853.501 | 21,002.501 | 20,327.021 | 18,921.226 | 21,455.153 | 19,809.863 | 25,641.18 | 26,168.084 | 23,111.808 | 24,374.65 |
| Other Expenses
| -173,017.059 | 24,315.287 | 26,858.479 | 25,389.427 | 26,094.37 | 26.145 | -798.952 | -725.046 | -928.007 | -254.068 | -962.209 | -1,076.003 | -2,024.103 | -2,012.939 | -1,162.795 | -1,253.183 | -638.863 |
| Operating Expenses
| 173,017.059 | 60,867.316 | 57,884.983 | 55,268.684 | 61,641.147 | 63,125.255 | 59,972.218 | 44,807.578 | 40,571.784 | 39,275.367 | 38,523.954 | 43,588.21 | 43,033.095 | 46,755.611 | 48,322.071 | 49,157.574 | 48,529.473 |
| Operating Income
| 7,745.6 | 7,970.051 | -811.828 | 3,052.874 | 3,467.587 | -2,656.973 | 2,010.979 | 2,330.412 | 1,706.488 | 2,253.004 | 2,187.114 | -4,318.831 | 3,749.041 | 1,088.514 | 2,955.652 | 4,241.207 | 6,802.777 |
| Operating Income Ratio
| 0.043 | 0.049 | -0.006 | 0.023 | 0.026 | -0.02 | 0.015 | 0.019 | 0.016 | 0.021 | 0.02 | -0.042 | 0.033 | 0.01 | 0.024 | 0.035 | 0.061 |
| Total Other Income Expenses Net
| 1,103.445 | -2,300.343 | -3,208.891 | -370.009 | -1,944.54 | -473.126 | -436.365 | -982.921 | 3,325.552 | -644.923 | -1,036.314 | -1,895.334 | -1,391.663 | 2,705.41 | -1,036.332 | -415.561 | 6,501.096 |
| Income Before Tax
| 8,849.045 | 5,669.707 | -4,020.719 | 2,682.866 | 1,523.047 | -3,130.1 | 1,574.614 | 1,347.491 | 5,032.04 | 1,608.081 | 1,150.799 | -6,214.165 | 2,357.378 | 3,793.925 | 1,919.319 | 3,825.646 | 13,303.874 |
| Income Before Tax Ratio
| 0.049 | 0.035 | -0.029 | 0.02 | 0.011 | -0.024 | 0.012 | 0.011 | 0.046 | 0.015 | 0.011 | -0.061 | 0.021 | 0.034 | 0.016 | 0.032 | 0.119 |
| Income Tax Expense
| 2,227.479 | 5,834.291 | -847.543 | 495.802 | 310.199 | -1,023.752 | 116.268 | 86.603 | 3,438.258 | 139.825 | -308.806 | -1,366.448 | 1,367.834 | 825.861 | 248.731 | 350.42 | 3,567.675 |
| Net Income
| 6,121.76 | -164.583 | -3,173.176 | 2,187.064 | 1,212.848 | -2,106.348 | 1,458.347 | 1,260.887 | 1,593.782 | 1,468.256 | 1,414.88 | -4,849.874 | 989.545 | 2,968.064 | 1,670.588 | 3,475.226 | 9,736.198 |
| Net Income Ratio
| 0.034 | -0.001 | -0.023 | 0.016 | 0.009 | -0.016 | 0.011 | 0.011 | 0.015 | 0.014 | 0.013 | -0.047 | 0.009 | 0.027 | 0.014 | 0.029 | 0.087 |
| EPS
| 225.81 | -5.92 | -113.82 | 79.91 | 44.49 | -76 | -69 | 55.52 | 66.24 | 61.37 | 58.45 | -201.64 | 40.91 | 120.79 | 66.24 | 127.61 | 343.47 |
| EPS Diluted
| 225.81 | -5.92 | -113.82 | 79.91 | 44.49 | -76 | -69 | 55.52 | 66.24 | 61.37 | 58.45 | -201.64 | 40.91 | 120.79 | 66.24 | 127.61 | 343.47 |
| EBITDA
| 25,066.89 | 10,155.371 | 3,167.08 | 7,425.865 | 6,980.787 | 773.684 | 3,928.219 | 4,214.254 | 3,078.834 | 4,201.422 | 4,216.641 | -2,368.774 | 4,855.033 | 2,218.637 | 6,610.677 | 4,216.983 | 3,367.863 |
| EBITDA Ratio
| 0.139 | 0.062 | 0.023 | 0.056 | 0.052 | 0.006 | 0.03 | 0.035 | 0.028 | 0.039 | 0.039 | -0.023 | 0.043 | 0.02 | 0.054 | 0.035 | 0.03 |